Jupiter Neurosciences, Inc. (JUNS) vs Lakewood-Amedex Biotherapeutics, Inc. (LABT)
A side-by-side comparison of Jupiter Neurosciences, Inc. and Lakewood-Amedex Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
JUNS
Jupiter Neurosciences, Inc.
$2.50HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
LABT
Lakewood-Amedex Biotherapeutics, Inc.
$0.84HealthcareDelayed quote: Oct 6, 2026, 12:23 PM EDT
Total return — JUNS vs LABT
growth of $100 · dividends reinvested · last 1yJUNS -91.6% (-91.6%/yr)LABT -99.0% (-99.0%/yr)JUNS compounded faster over this window
Log scale — wide-divergence pair
JUNS LABT
JUNS vs LABT: by the numbers
- •LABT is the larger company ($1M vs $1M market cap).
- •Both run net losses; LABT's is the smaller (0.00% vs -14220.12% net margin).
Metrics side by side
Valuation
| Metric | JUNS | LABT |
|---|---|---|
| P/S ratio | 18.73 | N/A |
| P/B ratio | N/A | 0.34 |
Profitability
| Metric | JUNS | LABT |
|---|---|---|
| Gross margin | 88.34% | 0.00% |
| Operating margin | -40873.19% | 0.00% |
| Net margin | -14220.12% | 0.00% |
| ROE | N/A | -169.64% |
| ROIC | -709.40% | -163.98% |
Growth (annualized)
| Metric | JUNS | LABT |
|---|---|---|
| Revenue CAGR (5Y) | -47.77% | N/A |
Go deeper
Dig into the metrics
Jupiter Neurosciences ROELakewood-Amedex Biotherapeutics ROEJupiter Neurosciences operating marginLakewood-Amedex Biotherapeutics operating marginJupiter Neurosciences revenue growthLakewood-Amedex Biotherapeutics revenue growthJupiter Neurosciences free cash flowLakewood-Amedex Biotherapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.